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Abstract
Pyrazinamide (PZA) is a first-line key drug used in combination with other agents for the 
treatment of tuberculosis (TB). Phenotypic and molecular assays for testing susceptibili-
ty of Mycobacterium tuberculosis (Mtb) to PZA have been developed, with the assay in liq-
uid medium at acidic pH in the Bactec MGIT 960 (M960) system being routinely used 
in the mycobacteriology laboratories. However, false resistance to PZA by this method 
was reported to occur by several investigators, mostly due to high Mtb inoculum, which 
may impair drug activity by increasing the pH of the medium. In this study, a revision 
of the literature on the issue of false resistance in the M960 PZA assay was performed. 
In the reports examined, all improvements of the M960 test proposed to decrease false 
resistant results were based on the use of reduced inoculum densities of Mtb cells, to be 
easily translated into laboratory practice.
PYRAZINAMIDE FOR TREATMENT  
OF TUBERCULOSIS
Tuberculosis (TB) is the main cause of death due to 
a single infectious agent worldwide, and drug-resistant 
forms of the disease are a major risk to global health se-
curity [1].  The current anti-TB therapy consists of a 
combination of the first-line drugs isoniazid (INH), ri-
fampicin (RIF), ethambutol (EMB) and pyrazinamide 
(PZA) given daily for 2 months, followed by RIF and 
INH administered daily for 4 months. Poor adherence 
to TB treatment leads to emergence of multidrug-re-
sistant (MDR) Mycobacterium tuberculosis (Mtb) strains 
(resistant at least to INH and RIF) and extensively 
drug-resistant (XDR) strains (MDR strains resistant to 
any fluoroquinolone and to at least one injectable sec-
ond-line drug, kanamycin, amikacin or capreomycin). 
At global level, in 2017 the World Health Organization 
(WHO) estimated that 558 000 people developed TB 
that was resistant to RIF, and that of these, 82% had 
MDR-TB [2]. 
PZA is a cornestone anti-TB drug active in the first 
two months of therapy. It is likely that during the early 
inflammatory stages of the TB disease, PZA kills intra-
cellular and semidormant tubercle bacilli living in the 
acidic environment of the phagolysosomes of activated 
macrophages. In the 1980s, the substitution of PZA for 
streptomycin (SM) in the regimen INH-RIF-EMB-SM 
shortened the course of TB therapy from 9-12 months 
to the current 6 months regimen, INH-RIF-EMB-PZA. 
The ability of PZA to shorten the in vivo therapy is of 
great importance. In this view, this drug is currently 
being considered in future anti-TB regimens in combi-
nation with new agents, including bedaquiline, delama-
nid, pretomanid, moxifloxacin, levofloxacin, linezolid in 
phase II and III trials [2]. 
MECHANISMS OF ACTION  
AND RESISTANCE OF PZA
The activity of PZA depends on the acidity of the cul-
ture medium, with the drug being active at pH lower 
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than 6. PZA is a prodrug which enters Mtb cells by pas-
sive diffusion. Inside the cytoplasm, the drug is convert-
ed into its active form pyrazinoic acid (POA) by the pyr-
azinamidase (PZase), an enzyme encoded by the pncA 
gene. Then, POA is expelled out of the cell through 
passive diffusion [3]. Under external acidic conditions, 
the POA is protonated and enters the cell by passive 
diffusion and a defective POA efflux mechanism. Fol-
lowing intracellular accumulation, POA kills Mtb by 
various mechanisms including disruption of membrane 
energy production, inhibition of trans-translation and 
inhibition of panthotenate and coA biosynthesis. 
Resistance to PZA is mostly generated by mutations 
in the pncA gene, but mutations in panD and rpsA genes 
may also be involved [4]. Several studies indicated that 
MDR Mtb strains were more likely to harbor PZA re-
sistance than non-MDR strains, with estimated preva-
lences being 16.2% for all TB cases and 60.5% for MDR 
cases [5]. The estimated global burden is 1.4 million 
PZA-resistant cases annually, including about 270 000 
in MDR patients. Recently, the WHO categorized PZA 
in the group C agents for use in longer MDR-TB regi-
mens, to be added to group A (levofloxacin or moxi-
floxacin, bedaquiline, linezolid) and B (clofazimine, ci-
closerine or terizidone) regimens, and when medicines 
from groups A and B cannot be used [6]. 
DRUG SUSCEPTIBILITY TESTING OF PZA
Drug susceptibility testing (DST) of PZA is challeng-
ing. Two main phenotypic assays are known, including 
the automated Bactec MGIT 960 system (MGIT; Bec-
ton Dickinson, Sparks, MD) performed by monitoring 
the growth of Mtb in liquid medium at pH 5.9 con-
taining 100 µg/ml of PZA, and the classic and modified 
Wayne’s methods, which assess activity of PZase on the 
basis of colorimetric changes at 100 µg/ml and 400 µg/
ml of PZA, respectively [5]. The PZA MGIT test is the 
more commonly used of these two methods, but false 
resistance in a multicenter study was recently reported, 
largely due to high Mtb inoculum, which may impair 
PZA activity by increasing the pH of the medium [7]. 
For this reason, the WHO considers the DST to PZA 
not reliable, and considers an acceptable practice to ad-
minister the drug in a regimen even when a laboratory 
demonstrates resistance [8]. However, PZA is counted 
as an effective agent when DST results confirm suscep-
tibility [6]. 
In the last years, genotypic PZA assays have also been 
developed, based on DNA sequencing to detect pncA 
mutations, which have been shown to correlate with 
PZA resistance [3, 9-10]. The sequencing of rpsA and 
panD genes provided only a 2% increase in sensitivity, 
and from 8% to 10% resistant strains without pncA, rpsA 
and panD mutations may point to alternative mecha-
nisms of resistance [10]. Even though pncA sequencing 
is a powerful tool for molecular diagnosis of PZA resis-
tance, a study reported that the countrywide prevalence 
of pncA mutations in Mtb isolates phenotypically resis-
tant to PZA varied from 45 to 100% [11].  Furthermore, 
in a large investigation of genetic surveillance conduct-
ed on 7 094 patients in highly endemic countries, the 
sensitivity for pncA sequencing compared with MGIT 
testing adjusted for the results of the Wayne’s test was 
only 54% [12]. The diversity of single nucleotide poly-
morphisms across the pncA gene complicates the de-
velopment of rapid molecular diagnostics, because not 
all mutations confer resistance, and not all susceptible 
strains lack mutations [5, 7]. For these reasons, also 
these molecular techniques are not yet approved by 
WHO for PZA DST [5, 11]. In this view, the whole-
genome sequence (WGS) may be useful to improve 
diagnosis. Indeed, the sensitivity of this technique for 
PZA DST was reported to be 91.3% in a recent study 
performed on 10 209 Mtb isolates assayed by WGS and 
various phenotypic DST [13]. However, this technol-
ogy is not yet routinely available in most laboratories 
worldwide, thus in consideration of this limitation, it is 
still necessary to perform culture-based PZA DST [7]. 
PREVENTION OF FALSE PZA RESISTANCES 
WHEN USING THE MGIT SYSTEM
Erroneous results indicating false PZA resistances 
when using the MGIT system were reported by several 
investigators. 
In 2009, Pandey et al. found that the MGIT test 
showed 54.2% false PZA resistance in comparison with 
pncA sequencing [14]. 
In 2010, Chedore et al. reported that 42% of 57 strains 
diagnosed as resistant by MGIT were false resistant in 
comparison with pncA sequencing, and with results 
obtained by the radiometric system BACTEC 460 TB 
(BACTEC) (Becton Dickinson), that was considered 
the gold standard [15]. Erroneous results by MGIT 
were attributed to various reasons including high con-
centration, volume and heterogeneity of the inoculum. 
Indeed, i) the concentration of inoculum was 2.5 times 
greater than in the BACTEC method, ii) the volume 
inoculated was 5 times greater than in BACTEC, iii) 
the bacilli were inoculated by a pipette in MGIT and by 
a fine-needle syringe in BACTEC, resulting in uneven 
distribution of bacilli due to “clumping”. It was suggest-
ed to retest all PZA-resistant isolates by the BACTEC, 
but this system was later withdrawn from the market by 
the manufacturer to avoid disposal of the radioactive 
waste, and was replaced by the MGIT system.
In 2011, Simons et al. found that in 69 strains re-
sulted to be PZA resistant by MGIT, 68.1% were false 
positives after a second MGIT analysis, and that pncA 
mutations could identify these false resistances correct-
ly [16]. Also these investigators pointed out that false 
phenotypic PZA resistance was due to large inocula 
which increased pH and thereby inactivated PZase. To 
improve DST, they recommended repeating the MGIT 
test, giving attention to the inoculum size, and perform-
ing mutation analysis as an adjunct to the MGIT assay.
In 2013, the Sweedish Institute for Communicable 
Disease Control reported that over the course of pro-
ficiency testing excercises, two out of six clinical labo-
ratories showed pronounced problems with false resis-
tance results, with a positive predictive value of only 
63% and 45%, respectively [17].
Piersimoni et al., in two papers published in 2013 
[18] and 2016 [19], respectively, retested a total of 82 
PZA-resistant strains by the BACTEC standard assay, 
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by reducing the inoculum volume of the MGIT test 
tubes from 0.5 ml to 0.25 ml. By this approach, false re-
sistance decreased by 71.1% and 51.4%, respectively, in 
comparison with standard MGIT assay. It was suggest-
ed that PZA resistant isolates should undergo a repeat 
DST using the reduced inoculum of 0.25 ml. In case of 
resistance, pncA gene sequencing should be performed, 
otherwise, the isolate should be reported as susceptible. 
Some investigators also suggested to reassess the criti-
cal concentration for PZA susceptibility [20, 21]. In the 
Piersimoni’s studies, both reduced inoculum and PZA 
testing at 200 µg/ml reduced false MGIT-resistances, 
however, only reduced inoculum allowed a clear separa-
tion between true- and false-resistant isolates.
In 2017, Morlock et al., during the course of a mul-
ticenter study coordinated by the US Centers for Dis-
ease Control and Prevention, also mitigated false PZA 
positivities by MGIT through the use of reduced inocu-
lum densities [7]. Twenty genetically and phenotypical-
ly characterized isolates were tested in ten independent 
laboratories by the standard PZA MGIT method (0.5 
ml of positive MGIT tubes transferred to test tubes con-
taining 100 µg/ml of PZA) and 1:2.5 and 1:5 dilutions 
of the positive tubes. By this approach, the percentages 
of resistant results that were false-resistant declined 
from 55.2% for the standard MGIT test to 28.8% and 
16.0% for the 1:2.5 and 1:5 diluted inocula, respective-
ly. These investigators reported that some strains were 
“always susceptible” regardless of inoculum concentra-
tion while other strains called “predominantly suscep-
tible” showed high degree of false resistance when the 
standard method was used. 
Finally, in 2017, Mustazzolu et al. tested 106 WHO 
strains with known pncA mutations by a slightly modi-
fied MGIT standard test [22]. A positive MGIT seed 
tube was allowed to settle for 20 to 30 min, then 1 ml 
was taken from the top surface, instead of lower down; 
of this volume, 0.5 ml was transferred to a 100 µg/ml 
PZA-containing test tube, and 0.5 ml of 1:10 dilution 
from the positive tube was used to inoculate the growth 
control tube without PZA. Using this easy variation, 
0.9% of strains were falsely resistant and no strains were 
falsely susceptible. Furthermore, when 10 of those 
strains were tested by 17 Italian independent laborato-
ries (a total of 68 resistant and 102 susceptible strains), 
false resistance was reported to be 4.7% by the standard 
method and 1.2% by the modified MGIT method. 
CONCLUSION
Overall, these observations provide compelling evi-
dence that to decrease false resistant results it is neces-
sary to reduce the inoculum in the MGIT PZA assay 
currently used worldwide. This purpose can be achieved 
by changing the method of drafting the initial inoculum, 
or changing PZA critical concentration. As suggested 
by Morlock et al. [7], clinical laboratories should vali-
date their modified method prior to routine implemen-
tation. However, large controlled studies using both 
MGIT and molecular methods should be performed by 
investigators and/or by the manufacturer of the current 
test, to modify the MGIT package of the PZA assay.
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